.Pharmacolibrary.Drugs.ATC.N.N06DX05 .Pharmacolibrary.Drugs.ATC.N.N06DX05| name: | Donanemab | |
| ATC code: | N06DX05 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 700 | mg |
| volume of distribution: | 3.07 | L |
| clearance: | 0.296 | L/day |
| other parameters in model implementation | ||
Donanemab is a humanized IgG1 monoclonal antibody that targets amyloid-beta plaques in the brain. It is being developed as a disease-modifying treatment for Alzheimer's disease and is currently under regulatory review, not yet fully approved for general use as of June 2024.
Population PK results in patients with early symptomatic Alzheimer’s disease; typical demographics: both sexes, older adults.